Vilin Bio Med revenue triples as September-half profit jumps
Key highlights
- Vilin Bio Med reported Rs 32.60 crore of revenue from operations for the half-year ended September 30, 2026, versus Rs 9.66 crore a year earlier.
- Vilin Bio Med's September 2026 half-year profit was Rs 1.28 crore, compared with Rs 15.17 lakh in September 2025.
- Vilin Bio Med's profit fell from Rs 1.78 crore in the March 2026 half-year as total expenses increased to Rs 30.84 crore.
- Vilin Bio Med's cost of materials consumed was Rs 29.08 crore, up from Rs 28.66 crore in the preceding half-year.
powered by IRIS

Vilin Bio Med Limited reported standalone revenue from operations of Rs 32.60 crore for the half-year ended September 30, 2026, more than triple Rs 9.66 crore a year earlier, while profit for the period increased to Rs 1.28 crore from Rs 15.17 lakh. Revenue was almost unchanged from the preceding March 2026 half-year, but profit declined from Rs 1.78 crore as expenses rose.
Know Vilin Bio Med inside out
Results, valuation, peers and who's buying, in one view.
What did Vilin Bio Med report for the September 2026 half-year?
Vilin Bio Med reported total revenue of Rs 32.60 crore for the half-year ended September 30, 2026, compared with Rs 9.66 crore in the corresponding half-year ended September 30, 2025. Revenue from operations was Rs 32.60 crore in the latest period, while other income was Rs 7,000. The operating revenue figure was 3.37 times the prior-year level, based on the reported standalone numbers.
Vilin Bio Med recorded profit before tax of Rs 1.76 crore, up from Rs 19.38 lakh a year earlier, and profit for the period of Rs 1.28 crore, against Rs 15.17 lakh. Basic and diluted earnings per equity share rose to Rs 0.84 from Rs 0.11. The statement recorded no exceptional items, no discontinued operations and no other comprehensive income for either September-half period.
Total expenses rose to Rs 30.84 crore in the September 2026 half-year from Rs 9.47 crore in September 2025. The increase in expenses was smaller than the Rs 22.94 crore increase in revenue from operations, leaving profit before tax Rs 1.57 crore higher year on year. Current tax was Rs 45.91 lakh and deferred tax expense was Rs 1.86 lakh.
How did Vilin Bio Med compare with the preceding half-year?
Vilin Bio Med's revenue from operations was effectively flat against the half-year ended March 31, 2026, at Rs 32.60 crore versus Rs 32.60 crore. The latest figure was Rs 10,000 higher, while other income declined to Rs 7,000 from Rs 12,000. Total revenue was therefore Rs 32.60 crore in both half-years after conversion to crore units.
Profit before tax fell to Rs 1.76 crore from Rs 2.65 crore in the March 2026 half-year, while profit for the period declined to Rs 1.28 crore from Rs 1.78 crore. Earnings per equity share also decreased to Rs 0.84 from Rs 1.26. The reported sequential reduction in profit before tax, Rs 89.78 lakh, closely matched the increase in total expenses.
Total expenses increased to Rs 30.84 crore from Rs 29.95 crore between the two half-years. Based on reported totals, profit for the period represented about 3.9% of total revenue in the September half, compared with about 5.5% in the March half. These percentages are calculations from the standalone financial statement and are not a margin measure stated by Vilin Bio Med.
Which expenses increased in Vilin Bio Med's September half?
Vilin Bio Med's cost of materials consumed was its largest reported expense at Rs 29.08 crore for the half-year ended September 30, 2026. This was Rs 41.91 lakh above the Rs 28.66 crore reported in the March 2026 half-year and Rs 20.11 crore above the Rs 8.97 crore reported a year earlier. The filing reported no purchases of stock in trade or inventory-change expense in the three half-year columns.
Employee benefit expense rose to Rs 89.60 lakh from Rs 55.80 lakh in the preceding half-year and Rs 18.29 lakh in the September 2025 half-year. Other expenses rose to Rs 66.26 lakh from Rs 52.36 lakh sequentially and Rs 17.78 lakh year on year. Together, these increases accompanied the Rs 89.78 lakh rise in total expenses from March 2026.
Depreciation and amortisation expense decreased to Rs 20.35 lakh from Rs 21.03 lakh in the March half-year, while finance cost fell to Rs 1,000 from Rs 11,000. Those reductions did not offset higher material, employee and other expenses. Compared with September 2025, depreciation increased from Rs 7.45 lakh, while finance cost fell from Rs 6.77 lakh.
Got a follow-up? Ask IRIS
What do Vilin Bio Med's balance-sheet figures show?
Vilin Bio Med reported total assets of Rs 39.44 crore as at September 30, 2026, compared with Rs 34.94 crore as at March 31, 2026. Current assets increased to Rs 31.67 crore from Rs 27.38 crore, while non-current assets rose to Rs 7.77 crore from Rs 7.56 crore. Shareholders' funds were Rs 29.65 crore, up from Rs 28.37 crore.
Inventories increased to Rs 10.49 crore at September 30 from Rs 7.22 crore at March 31, while trade receivables rose to Rs 18.71 crore from Rs 15.96 crore. Cash and cash equivalents moved in the other direction, decreasing to Rs 21.52 lakh from Rs 1.47 crore. Other current assets declined to Rs 1.68 crore from Rs 2.31 crore.
Current liabilities were Rs 9.64 crore at September 30, 2026, compared with Rs 6.44 crore at March 31, 2026. Trade payables other than micro, small and medium enterprises were Rs 6.08 crore, up from Rs 3.36 crore, and short-term provisions increased to Rs 1.27 crore from Rs 81.73 lakh. Other current liabilities were Rs 2.25 crore, compared with Rs 2.06 crore.
What did Vilin Bio Med disclose about reporting and operations?
Vilin Bio Med's board approved the unaudited standalone financial results for the half-year ended September 30, 2026 on November 14, 2026. The company said its Audit Committee reviewed the results and its statutory auditors issued a limited review report. The board meeting began at 3:00 p.m. and concluded at 5:10 p.m. on that date.
Vilin Bio Med stated that it operates in a single segment, meaning segment reporting was not applicable. The filing consequently provides no split of the Rs 32.60 crore September-half revenue or Rs 1.28 crore profit by product, customer group, geography or business line. It also says prior-period figures were regrouped or reclassified where necessary to conform with the current presentation.
For the financial year ended March 31, 2026, Vilin Bio Med reported revenue from operations of Rs 42.26 crore and profit for the period of Rs 1.93 crore. The September 2026 half-year's revenue was about 77% of that prior full-year revenue, while its profit was about 66% of the prior full-year amount. This compares six months with 12 months and does not indicate a full-year outcome.
Conclusion
Vilin Bio Med's September 2026 half-year statement shows a large year-on-year expansion, with operating revenue rising to Rs 32.60 crore from Rs 9.66 crore and profit increasing to Rs 1.28 crore from Rs 15.17 lakh. Against the immediately preceding half-year, however, nearly unchanged revenue combined with a Rs 89.78 lakh increase in expenses, resulting in lower profit before tax and profit for the period.
The filing does not disclose a revenue target, expansion plan or operating guidance for subsequent periods. The next disclosed procedural event was the reopening of the trading window 48 hours after the declaration of standalone results approved on November 14, 2026; later financial statements will show whether revenue, material costs, inventories and receivables change after September 2026.


